
Opinion|Videos|June 11, 2024
Key Treatment Considerations for Patients Diagnosed With PNH
Dr Haumschild drives a discussion surrounding impactful PNH treatment strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the goals and primary considerations in developing a treatment plan for patients with paroxysmal nocturnal hemoglobinuria?
Advertisement
Related to this article

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
Emerging Threats to Cell and Gene Therapy Access
4
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
5

